August 2018 Corporate Presentation

Mostly the same as last month's slides. Timeline overview slide reflects revised xB3-001 timeline as discussed in the recent MD&A. Interesting statement on slide 7 about gene therapy studies starting in Q4 2018 (good catch by digitel on Stockhouse). Hmmmm. An alternative strategy for xB3-007 and xB3-008 programs or an entirely new program? Enzyme replacement in 007/008 programs can be accomplished by delivering xB3-enzyme fusion to patients or delivering a gene therapy that encodes a xB3-enzyme fusion. For example, gene therapy targeting liver that allows liver cells to make xB3-enzyme fusion. Furthermore, the gene therapy vector could even be xB3-modified/facilitated so that gene therapy crosses BBB and turns cells in brain into enzyme making factories. A very curious gene therapy teaser. 

BearDownAZ